Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ALKS NASDAQ:BOLT NASDAQ:DVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.02+0.7%$20.52$13.40▼$25.23$3.49B0.641.98 million shs2.39 million shsALKSAlkermes$29.38+0.5%$30.16$22.90▼$36.45$4.82B0.441.74 million shs1.59 million shsBOLTBolt Biotherapeutics$6.04+2.9%$6.31$5.20▼$15.60$11.25M0.8911,496 shs16,843 shsDVAXDynavax Technologies$10.59+2.8%$10.10$9.22▼$14.63$1.24B1.032.16 million shs1.90 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.67%-1.59%-4.37%+40.51%+28.80%ALKSAlkermes+0.51%+1.35%-7.35%+1.98%+20.56%BOLTBolt Biotherapeutics+2.90%+0.67%-6.50%-10.91%-58.91%DVAXDynavax Technologies+2.82%+5.27%+3.42%-11.97%-5.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals4.6825 of 5 stars4.43.00.00.03.24.22.5ALKSAlkermes4.9317 of 5 stars4.43.00.04.23.52.51.9BOLTBolt Biotherapeutics3.4106 of 5 stars3.23.00.00.02.83.31.3DVAXDynavax Technologies4.3646 of 5 stars3.32.00.04.71.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.71Moderate Buy$27.8832.61% UpsideALKSAlkermes 2.83Moderate Buy$40.0036.15% UpsideBOLTBolt Biotherapeutics 2.33Hold$50.00727.81% UpsideDVAXDynavax Technologies 2.50Moderate Buy$24.00126.63% UpsideCurrent Analyst Ratings BreakdownLatest DVAX, ACAD, ALKS, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.006/26/2025ACADACADIA PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$37.006/26/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/26/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.006/23/2025ACADACADIA PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.006/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/6/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.006/5/2025ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/5/2025ACADACADIA PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Hold$18.00 ➝ $23.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/21/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.00 ➝ $35.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.67$0.71 per share29.62$4.40 per share4.78ALKSAlkermes$1.56B3.11$2.67 per share11.02$9.05 per share3.25BOLTBolt Biotherapeutics$7.69M1.51N/AN/A$29.89 per share0.20DVAXDynavax Technologies$277.25M4.59$0.16 per share65.04$4.54 per share2.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3715.3427.664.5022.97%17.46%10.75%8/5/2025 (Estimated)ALKSAlkermes$367.07M$2.0914.0621.451.8223.30%27.52%17.98%7/23/2025 (Estimated)BOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)DVAXDynavax Technologies$27.31M-$0.52N/A21.61N/A-20.39%3.59%2.20%8/5/2025 (Estimated)Latest DVAX, ACAD, ALKS, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$263.07 millionN/A8/5/2025Q2 2025DVAXDynavax Technologies$0.12N/AN/AN/A$87.55 millionN/A7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/ABOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80ALKSAlkermesN/A3.332.92BOLTBolt Biotherapeutics0.483.133.13DVAXDynavax Technologies0.4911.9310.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ALKSAlkermes95.21%BOLTBolt Biotherapeutics86.70%DVAXDynavax Technologies96.96%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals28.30%ALKSAlkermes4.40%BOLTBolt Biotherapeutics30.90%DVAXDynavax Technologies2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million120.00 millionOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableDVAX, ACAD, ALKS, and BOLT HeadlinesRecent News About These CompaniesCitizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31July 7 at 2:52 PM | finance.yahoo.comCitizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31July 6 at 5:44 AM | insidermonkey.comDVAX - Dynavax Technologies Corp Key Metrics - MorningstarJuly 5, 2025 | morningstar.comMDVAX Dynavax Technologies Corporation - Seeking AlphaJune 28, 2025 | seekingalpha.com93,841 Shares in Dynavax Technologies Corporation (NASDAQ:DVAX) Acquired by Advisor Resource CouncilJune 21, 2025 | marketbeat.comSG Americas Securities LLC Reduces Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)June 21, 2025 | marketbeat.comExchange Traded Concepts LLC Cuts Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)June 18, 2025 | marketbeat.comChicago Capital LLC Has $69.32 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)June 17, 2025 | marketbeat.comDynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by GAMMA Investing LLCJune 16, 2025 | marketbeat.comDynavax re-elects all board members, despite Deep Capital's push to changeJune 11, 2025 | msn.comDynavax elects all four of its nominees after Deep Track proxy fightJune 11, 2025 | reuters.comDynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual MeetingJune 11, 2025 | prnewswire.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the BoardroomJune 9, 2025 | finance.yahoo.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...June 9, 2025 | gurufocus.comDeep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final ...June 9, 2025 | gurufocus.comDeep Track Capital Pushes for Board Changes at Dynavax Technologies Corp (DVAX) | DVAX stock newsJune 9, 2025 | gurufocus.comDynavax Technologies Corp (DVAX) Urges Stockholders to Support Director Nominees | DVAX stock newsJune 9, 2025 | gurufocus.comDynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual MeetingJune 9, 2025 | prnewswire.comVaccine maker Dynavax's future hangs in balance amid activist investor showdownJune 5, 2025 | bizjournals.comGlass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax TechnologiesJune 5, 2025 | finance.yahoo.comGlass Lewis backs two of Deep Track's four nominees in Dynavax fightJune 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverDVAX, ACAD, ALKS, and BOLT Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.02 +0.14 (+0.67%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$21.02 +0.00 (+0.02%) As of 07/8/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Alkermes NASDAQ:ALKS$29.38 +0.15 (+0.51%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$29.58 +0.20 (+0.68%) As of 07/8/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Bolt Biotherapeutics NASDAQ:BOLT$6.04 +0.17 (+2.90%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$6.03 -0.01 (-0.15%) As of 07/8/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Dynavax Technologies NASDAQ:DVAX$10.59 +0.29 (+2.82%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$10.36 -0.23 (-2.12%) As of 07/8/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
